The ‘Skinny Labels’ Case Will Have A Huge Impact On The Affordability Of Healthcare

The US Supreme Court is being urged by the Biden administration to weigh in on the issue of "skinny labeling" in generic drug competition, as the court battle between Teva and GSK over patent infringements of the high blood pressure drug Coreg may determine whether drug prices can be kept higher for longer or if they will go down to an affordable level for consumers.

Bild durch KI erstellt